Please enter keyword
OK
Please enter keyword
OK
English
Introduction of Biocytogen Animal Centers
Since 2014, Biocytogen has been operating three animal centers distributed in Nantong (Jiangsu, P.R.China), Daxing (Beijing, P.R.China), and Boston (USA) under the brand of "Biocytogen Animals". The ultimate goal is to provide superior supports to global customers for their scientific research as well as new drug discovery using our innovative genetically engineered models (GEMs). Through implementing strict, scientific, and standard operating procedures, and a highly efficient facility management system, the animal centers have performed the same or even higher standards for critical quality-control testing to identify microbial contamination. With innovative animal models, high standard quality-control program, and tailored services, the animal centers have contributed significant shares of Biocytogen to support and promote the rapid growth of the biopharma industry throughout the world.
3300+
Animal/Cell Models
TOP10
MNC Cooperation
3times
AAALAC Certification
150000+
Cages
55000
Animal Center
Certifications
AAALAC certificate
Laboratory animal productio...
Laboratory animal use permi...
New high-tech enterprise
Animal export qualification
More
Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2023, 150 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
More